Iranian Journal of Pediatrics

Published by: Kowsar

Effects of Intravitreal Anti-VEGF Therapy on the Clinical Course of Bronchopulmonary Dysplasia

Fahri Ovali 1 , Huseyin Yetik 2 , * , Abdulhamit Tuten 1 , Sevilay Topcuoglu 1 and Murat Gunay 3
Authors Information
1 Department of Neonatology, Zeynep Kamil Maternity and Children’s Training and Research Hospital, Istanbul, Turkey
2 Department of Ophthalmology, Istanbul Univesity, Cerrahpasa Medical Faculty, Department of Ophthalmology, Surp Pirgic Armenian Hospital, Istanbul, Turkey
3 Department of Ophthalmology, Zeynep Kamil Maternity and Children’s Training and Research Hospital, Istanbul, Turkey
Article information
  • Iranian Journal of Pediatrics: December 2016, 26 (6); e4637
  • Published Online: July 11, 2016
  • Article Type: Research Article
  • Received: January 2, 2016
  • Revised: May 21, 2016
  • Accepted: June 10, 2016
  • DOI: 10.5812/ijp.4637

To Cite: Ovali F, Yetik H, Tuten A, Topcuoglu S, Gunay M. Effects of Intravitreal Anti-VEGF Therapy on the Clinical Course of Bronchopulmonary Dysplasia, Iran J Pediatr. 2016 ; 26(6):e4637. doi: 10.5812/ijp.4637.

Abstract
Copyright © 2016, Growth & Development Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7): 1723-9[DOI][PubMed]
  • 2. Fakhoury KF, Sellers C, Smith EO, Rama JA, Fan LL. Serial measurements of lung function in a cohort of young children with bronchopulmonary dysplasia. Pediatrics. 2010; 125(6): 1441-7[DOI][PubMed]
  • 3. Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol. 2006; 30(4): 179-84[DOI][PubMed]
  • 4. Hoo AF, Dezateux C, Henschen M, Costeloe K, Stocks J. Development of airway function in infancy after preterm delivery. J Pediatr. 2002; 141(5): 652-8[DOI][PubMed]
  • 5. Hjalmarson O, Sandberg K. Abnormal lung function in healthy preterm infants. Am J Respir Crit Care Med. 2002; 165(1): 83-7[DOI][PubMed]
  • 6. Jones M. Effect of preterm birth on airway function and lung growth. Paediatr Respir Rev. 2009; 10 Suppl 1: 9-11[DOI][PubMed]
  • 7. Jobe AH. The new bronchopulmonary dysplasia. Curr Opin Pediatr. 2011; 23(2): 167-72[DOI][PubMed]
  • 8. Support Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network , Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010; 362(21): 1959-69[DOI][PubMed]
  • 9. Vento M, Moro M, Escrig R, Arruza L, Villar G, Izquierdo I, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. Pediatrics. 2009; 124(3): 439-49[DOI][PubMed]
  • 10. Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015; 253(10): 1677-83[DOI][PubMed]
  • 11. Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev. 2012; 88(12): 937-41[DOI][PubMed]
  • 12. Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmstrom G. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. 2013; 91(2): 170-5[DOI][PubMed]
  • 13. Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008; 28(3 Suppl)-8[DOI][PubMed]
  • 14. Fierson WM, American Academy of Pediatrics Section on O, American Academy of O, American Association for Pediatric O, American Association of Certified O. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013; 131(1): 189-95[DOI][PubMed]
  • 15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36(4): 331-5[PubMed]
  • 16. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000; 17(12): 1503-10[PubMed]
  • 17. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46(2): 726-33[DOI][PubMed]
  • 18. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005; 293(12): 1509-13[DOI][PubMed]
  • 19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114(5): 855-9[DOI][PubMed]
  • 20. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005; 109(3): 227-41[DOI][PubMed]
  • 21. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009; 148(5): 647-56[DOI][PubMed]
  • 22. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000; 279(3)-7[PubMed]
  • 23. Lassus P, Turanlahti M, Heikkila P, Andersson LC, Nupponen I, Sarnesto A, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med. 2001; 164(10 Pt 1): 1981-7[DOI][PubMed]
  • 24. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol. 2001; 281(4)-10[PubMed]
  • 25. Maniscalco WM, Watkins RH, Pryhuber GS, Bhatt A, Shea C, Huyck H. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol. 2002; 282(4)-23[DOI][PubMed]
  • 26. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol. 1993; 264(4 Pt 1)-1002[PubMed]
  • 27. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, Akeson AL. VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol. 2004; 287(1)-42[DOI][PubMed]
  • 28. Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation. 2005; 112(16): 2477-86[DOI][PubMed]
  • 29. Lopez E, Boucherat O, Franco-Montoya ML, Bourbon JR, Delacourt C, Jarreau PH. Nitric oxide donor restores lung growth factor and receptor expression in hyperoxia-exposed rat pups. Am J Respir Cell Mol Biol. 2006; 34(6): 738-45[DOI][PubMed]
  • 30. Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2010; (12)[DOI][PubMed]
  • 31. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP. Plasma vascular endothelial growth factor in severe sepsis. Shock. 2005; 23(1): 35-8[PubMed]
  • 32. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy. 2003; 33(5): 595-9[PubMed]
  • 33. Kanazawa H, Asai K, Hirata K, Yoshikawa J. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med. 2003; 114(5): 354-8[PubMed]
  • 34. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995; 1(10): 1024-8[PubMed]
  • 35. Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, et al. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol. 2010; 150(2): 223-229 e1[DOI][PubMed]
  • 36. Nakao S, Arima M, Ishikawa K, Kohno R, Kawahara S, Miyazaki M, et al. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2012; 53(7): 4323-8[DOI][PubMed]
  • 37. Maitre B, Boussat S, Jean D, Gouge M, Brochard L, Housset B, et al. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J. 2001; 18(1): 100-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments